Conatus Pharmaceuticals (CNAT) Tops Q4 EPS by 7c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q4 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c